- Home
- GENC vs NKTX Comparison
GENC vs NKTX Comparison
Compare GENC & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENC
- NKTX
- Stock Information
- Founded
- GENC 1894
- NKTX 2015
- Country
- GENC United States
- NKTX United States
- Employees
- GENC N/A
- NKTX N/A
- Industry
- GENC Construction/Ag Equipment/Trucks
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- GENC Industrials
- NKTX Health Care
- Exchange
- GENC Nasdaq
- NKTX Nasdaq
- Market Cap
- GENC 181.9M
- NKTX 170.8M
- IPO Year
- GENC N/A
- NKTX 2020
- Fundamental
- Price
- GENC $11.54
- NKTX $1.81
- Analyst Decision
- GENC
- NKTX Strong Buy
- Analyst Count
- GENC 0
- NKTX 6
- Target Price
- GENC N/A
- NKTX $15.00
- AVG Volume (30 Days)
- GENC 32.1K
- NKTX 2.5M
- Earning Date
- GENC 05-09-2025
- NKTX 05-08-2025
- Dividend Yield
- GENC N/A
- NKTX N/A
- EPS Growth
- GENC 35.02
- NKTX N/A
- EPS
- GENC 1.11
- NKTX N/A
- Revenue
- GENC $113,116,000.00
- NKTX N/A
- Revenue This Year
- GENC N/A
- NKTX N/A
- Revenue Next Year
- GENC N/A
- NKTX N/A
- P/E Ratio
- GENC $10.44
- NKTX N/A
- Revenue Growth
- GENC 5.44
- NKTX N/A
- 52 Week Low
- GENC $10.80
- NKTX $1.31
- 52 Week High
- GENC $24.88
- NKTX $8.53
- Technical
- Relative Strength Index (RSI)
- GENC 43.40
- NKTX 54.82
- Support Level
- GENC $11.12
- NKTX $1.67
- Resistance Level
- GENC $11.97
- NKTX $1.84
- Average True Range (ATR)
- GENC 0.65
- NKTX 0.14
- MACD
- GENC -0.00
- NKTX 0.03
- Stochastic Oscillator
- GENC 50.34
- NKTX 68.42
About GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About NKTX Nkarta Inc.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.